Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Palatin Technologies, Inc. (PTN)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.4200+0.0270 (+6.87%)
At close: 04:00PM EST
0.4200 0.00 (0.00%)
After hours: 07:19PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3930
Open0.3800
Bid0.4100 x 1000
Ask0.4200 x 1800
Day's Range0.3800 - 0.4298
52 Week Range0.3300 - 1.3000
Volume2,387,601
Avg. Volume9,298,633
Market Cap97.165M
Beta (5Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)-0.1550
Earnings DateFeb 15, 2022 - Feb 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.33
  • PR Newswire

    Palatin Announces Presentation at the 2022 Crohn's and Colitis Congress

    Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced a presentation of the positive effects of PL8177 on treating ulcerative colitis in an animal disease model, including genomic data characterizing the anti-inflammatory effects of melanocortin agonists. The poster presentation of the efficacy and cellular and molecular effects of the me

  • PR Newswire

    Palatin to Present at H.C. Wainwright BioConnect Conference

    Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced that the Company will present and host one-on-one meetings at the H.C. Wainwright BioConnect Virtual Conference being held January 10–13, 2022.

  • Zacks

    Palatin (PTN) Begins Phase III Study For Dry Eye Disease

    Palatin (PTN) commences the pivotal phase III study evaluating PL9643 for the treatment of dry eye disease. Top-line data from the same is expected in the second half of 2022.

Advertisement
Advertisement